Top 3 Canadian Cannabis Stocks to Watch in February 2026The Canadian cannabis sector continues to evolve in early 2026. Although volatility remains, investor interest is returning. Regulatory discussions in the United States are once again gaining momentum. Because of that, Canadian operators with U.S. exposure are drawing attention. Many investors are watching companies positioned for cross-border expansion.Canada remains a mature recreational market. However, growth there has slowed compared to earlier ye ...

Industry Overview - The cannabis industry has evolved significantly, with a cultural shift towards legal cannabis impacting market dynamics [1] - Investors are increasingly interested in marijuana stocks as a way to participate in the industry without the complexities of starting a cannabis business [2] Investment Opportunities - Publicly traded cannabis companies provide an opportunity for investors to enter the market with lower capital requirements [2] - The cannabis sector offers various companies and sectors for diversification in investment portfolios [2] Market Volatility - Cannabis stocks are noted for their volatility, necessitating careful monitoring of market changes [3] Key Companies - **Aurora Cannabis Inc.**: Engages in the production, distribution, and sale of cannabis products, recently expanding its medical portfolio in Australia and New Zealand [4][5] - **Cronos Group Inc.**: Involved in the cultivation, production, distribution, and marketing of cannabis products in Canada and internationally [6] - **Organigram Global Inc.**: Focuses on the production and sale of cannabis products in Canada, recently reporting strong fiscal earnings [9] Financial Highlights of Organigram - Gross Revenue: $97.3 million, a 46% increase year-over-year [12] - Net Revenue: $63.5 million, a 49% increase year-over-year [12] - International Revenue: $5.0 million, a 51% increase year-over-year [12] - Adjusted EBITDA: $5.3 million, a 273% increase year-over-year [12] - Market Share: 1 in vapes, milled flower, and concentrates; 2 in pre-rolls; 3 in edibles and dried flower in Canada [12]

Core Thesis - Cronos Group Inc. is experiencing a bullish sentiment driven by renewed interest from the White House in rescheduling marijuana, leading to significant stock price increases and a positive outlook for the company's long-term positioning [3][4]. Company Overview - Cronos Group Inc. is a cannabinoid company involved in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally [3]. Regulatory Changes - Plans to reclassify marijuana as a Schedule III substance could significantly reduce regulatory and tax burdens for the U.S. cannabis industry, which is expected to benefit Cronos Group [4][5]. - A Schedule III classification would allow cannabis operators to deduct normal operating expenses and access standard tax credits, enhancing cash flow and profitability potential for Cronos Group [5]. Strategic Positioning - Cronos Group is strategically backed by Altria Group and has existing U.S. exposure through PharmaCann, which operates 51 dispensaries across multiple states, positioning the company favorably ahead of potential federal legalization [5][6]. - Management views Canada as a pilot market, with the U.S. and Europe representing significant long-term growth opportunities as regulations evolve [6]. Market Performance - Since the initial bullish thesis, Cronos Group's stock has increased by approximately 67%, outperforming peers and cannabis ETFs, as investors anticipate improved fundamentals and market access [4]. Future Outlook - The potential rescheduling of marijuana could accelerate medical research and FDA-approved cannabis applications, further supporting the investment case for Cronos Group [7]. - The combination of improving regulatory momentum, tax normalization, strategic U.S. optionality, and disciplined long-term planning reinforces the attractiveness of Cronos Group as a long-term investment [8].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend driven by tariffs [5][6] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities without the associated premium costs [9] Market Trends - The article discusses the broader trends of AI, energy, tariffs, and onshoring, indicating that this company is strategically aligned with these developments [6][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the importance of investing in AI-related companies [12] Future Outlook - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act quickly [15][19] - The company is described as undervalued, trading at less than seven times earnings, which presents a compelling investment opportunity in the context of the AI and energy sectors [10][11]

Group 1: Market Overview - Cannabis stocks to watch include Tilray Brands, Canopy Growth, Aurora Cannabis, Silver Spike Investment, and Cronos Group, identified by MarketBeat's stock screener tool [2] - Cannabis stocks are characterized by higher regulatory and legal risks, and they tend to be more volatile than the broader market due to changing laws and consumer demand [2] Group 2: Company Profiles - **Tilray Brands (TLRY)**: Engages in research, cultivation, processing, and distribution of medical cannabis, operating in multiple countries including Canada, Australia, and Germany [3] - **Canopy Growth (CGC)**: Involved in the production, distribution, and sale of cannabis and hemp-based products, primarily in the U.S., Canada, and Germany, with operations segmented into Canada Cannabis and International Markets Cannabis [3] - **Aurora Cannabis (ACB)**: Produces and sells cannabis products in Canada and internationally, operating through Canadian Cannabis, European Cannabis, and Plant Propagation segments [4] - **Silver Spike Investment (SSIC)**: A specialty finance company that invests in the cannabis ecosystem through direct loans and equity ownership of privately held cannabis companies [4] - **Cronos Group (CRON)**: Engages in the cultivation and marketing of cannabis products in Canada, Israel, and Germany, offering a variety of products under several brands [5]

Core Insights - U.S. equities have seen a decline in dominance, with valuation gaps narrowing from 54% above global peers at the end of 2024 to about 42% by mid-April 2025, indicating a potential shift in market leadership [2] - J.P. Morgan's forward-looking estimates suggest that developed international markets, including Canada, could outperform U.S. equities over the next decade, with projected annual returns of 8.1% for EAFE markets compared to 6.7% for the U.S. [3] - Canadian equities provide diversification benefits, reducing reliance on U.S. mega-cap stocks while offering exposure to various economic drivers such as commodities and energy [4] Canadian Stocks Overview - A list of 10 high-growth Canadian stocks has been compiled, focusing on companies with over 20% revenue growth in the past five years [5][7] - The methodology involved using the Finviz stock screener and analyzing hedge fund sentiment from Insider Monkey's database as of Q3 2025 [7][8] Draganfly Inc. (NASDAQ:DPRO) - Draganfly Inc. has achieved a 5-year revenue growth of 35.71% and has 6 hedge fund holders [9] - The company reported Q3 2025 revenue of $2.155 million, a 14.4% year-over-year increase, with strong demand in defense and public safety markets [10] - Draganfly is expanding its commercial footprint through partnerships and has integrated its drones with advanced detection systems for search-and-rescue missions [11][12] Cronos Group Inc. (NASDAQ:CRON) - Cronos Group has a 5-year revenue growth of 37.71% and is supported by 16 hedge fund holders [13] - The company reported consolidated net revenue of $36.3 million in Q3 2025, a 6% year-over-year increase, driven by the success of its Spinach brand [14] - Cronos maintains a strong balance sheet with no debt and approximately $824 million in cash and equivalents, positioning it well within the cannabis industry [13][15]

Industry Overview - The cannabis sector is experiencing growth despite historical volatility, with expectations for significant developments by 2026 that could benefit shareholders [1][2] - Recent legislative changes in the U.S., including the reversal of the 2018 farm bill and an executive order to reschedule cannabis, have sparked speculation about the future profitability for legal operators [2] Company Highlights - **Cronos Group Inc.**: Engages in the cultivation, production, distribution, and marketing of cannabis products internationally. Recently entered the Netherlands market by acquiring CanAdelaar B.V., the largest cannabis company in the Netherlands, which is seen as a strategic move to expand its footprint in Europe [3][4][5] - **Aurora Cannabis Inc.**: Focuses on the production and distribution of cannabis products. The company has made significant advancements in disease resistance research, moving from research to production trials of cultivars with verified PM2 resistance [6][7][8] - **SNDL Inc.**: Engages in the production and sale of cannabis products for the adult-use market in Canada. Recently received approval for a share repurchase program, allowing the company to repurchase up to C$100 million of its outstanding common shares [9][10]

Core Insights - Tilray Brands (TLRY) achieved record net revenues of $217.5 million in Q2 of fiscal 2026, marking a 3% year-over-year increase, primarily driven by strong international operations [1][8] Financial Performance - The Distribution business was the main contributor to revenue growth, increasing by 26% year-over-year to $85.3 million, supported by competitive pricing and favorable foreign exchange impacts [1][2] - The international cannabis segment saw a significant 36% increase in Q2, prompting the company to reduce shipments to the Canadian wholesale market in favor of higher-margin international markets [2][8] - Wellness segment revenues remained flat, with growth in Hi-Ball and the Ingredient Channel offset by challenges in the club retail channel [4] Market Position and Strategy - The Beverage business faced challenges due to headwinds in the craft beer segment and ongoing portfolio optimization efforts, but the company anticipates that upcoming retailer product resets will enhance brand visibility and align product offerings with consumer preferences [3] - TLRY's stock has outperformed the industry, with a 58.4% increase over the past six months compared to a 6.5% decline in the industry [7] Valuation Metrics - TLRY is currently trading at a forward Price-to-Sales (P/S) ratio of 1.18X, which is higher than its historical median but below the industry average of 3.05X [9]

Industry Overview - The cannabis industry is evolving with renewed optimism as investors look toward 2026, with Canadian companies at the forefront of global expansion due to strong medical programs and increasing international demand [1][2] - Investors face challenges such as volatility, regulation, and changing consumer trends [1] Company Summaries Tilray Brands Inc. (TLRY) - Tilray is one of the largest cannabis and consumer wellness companies in Canada, operating in Canada, Europe, Latin America, and emerging medical markets [2] - The company does not own U.S. cannabis dispensaries but partners with licensed distributors, allowing for brand expansion while remaining compliant [2] - Recent financial performance shows gradual improvement, with revenue growth from both cannabis and beverage operations, although profitability remains challenging due to operating expenses and restructuring costs [4] - Investors are optimistic about potential catalysts such as expanding international medical programs and regulatory changes, but the stock may experience price swings [4] Cronos Group Inc. (CRON) - Cronos is a global cannabis and cannabinoid company focused on developing branded products for adult-use and medical markets, emphasizing quality and innovation [6] - The company collaborates with licensed partners instead of owning U.S. dispensaries, allowing for cautious growth while remaining compliant [6] - Financially, Cronos has reported steady revenue growth supported by strong demand for premium products, maintaining a solid balance sheet and improving gross margins [8] - Despite periodic net losses, the company's disciplined approach to growth appeals to investors seeking stability [8] Aurora Cannabis Inc. (ACB) - Aurora is a recognized cannabis producer in Canada, heavily involved in medical cannabis across multiple regulated markets [9] - The company focuses on export partnerships and compliant product channels instead of operating U.S. dispensaries [9] - Aurora's financial performance reflects a strategic shift toward profitability, with improved gross margins and reduced operating expenses [11] - The company has achieved positive adjusted earnings recently, indicating operational progress, and is expected to continue growth in international medical markets [11]

Core Insights - The cannabis sector is expected to experience significant changes in stock performance in 2026, driven by the rescheduling of cannabis to a Class 3 substance, which may lead to improved business operations and stronger equity valuations [1][2] - Investor sentiment is anticipated to shift towards a focus on business performance rather than speculation, attracting long-term institutional investors who previously avoided the sector due to high risks [2][3] Industry Overview - The cannabis sector's growth will increasingly favor companies that demonstrate effective execution and responsible capital management, positioning themselves as sustainable consumer and healthcare businesses rather than merely regulatory trades [3] - More states are preparing to vote on cannabis legalization and other regulatory matters, indicating a potential ramp-up in market activity for the 2026 trading year [3] Company Highlights - **Tilray Brands, Inc.**: Engages in the research, cultivation, processing, and distribution of medical cannabis products across multiple regions, with a second quarter fiscal Year 2026 report scheduled for January 8 [4] - **Cronos Group Inc.**: Recently entered the Netherlands cannabis market through the acquisition of CanAdelaar B.V., Europe's largest adult-use cannabis company, which is expected to enhance its strategic footprint in Europe [7][9] - **Aurora Cannabis Inc.**: Launched a new product, Daily Special, in Germany, aimed at providing high-quality and affordable medical cannabis, showcasing its commitment to the European market [11]